TME Pharma

TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned. 

Updated corporate presentation with ESMO 15 Sept 2024 Oral Presentation data showing statistically significant improvement in survival of NOX-A12 + anti-VEGF + Radiotherapy

Corporate Presentation

Press Release 2025, July 08 08:00 a.m. TME Pharma: Termination of the liquidity contract 2025, June 30 06:00 p.m. TME Pharma announces new treasury investment policy 2025, June 27 06:00 p.m. TME Pharma provides results of final exercise of Warrants Z

Events NEAUX CANCER 4th ANNUAL CAGLA CONFERENCE Aram Mangasarian March 27 – 29 | New Orleans, USA Latest Analyst Report Invest Securities Jamila El Bougrini, PhD 2025, April 29 (EN/FR)